An Open-Label Randomized Phase II Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Phase I Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin.

Trial Profile

An Open-Label Randomized Phase II Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Phase I Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 17 Oct 2015

At a glance

  • Drugs P 276 (Primary) ; Carboplatin; Gemcitabine
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Sep 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 04 Dec 2013 Planned end date changed from 1 Nov 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov.
    • 18 Jul 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top